Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 2
2006 2
2008 2
2010 4
2011 1
2012 2
2013 7
2014 1
2015 4
2016 6
2017 2
2018 6
2019 5
2020 10
2021 9
2022 12
2023 11
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Results by year

Filters applied: . Clear all
Page 1
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.
Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN, Noyes DR, Montoya LB, Curry W, Pilon-Thomas SA, Chiappori AA, Tanvetyanon T, Kaye FJ, Thompson ZJ, Yoder SJ, Fang B, Koomen JM, Sarnaik AA, Chen DT, Conejo-Garcia JR, Haura EB, Antonia SJ. Creelan BC, et al. Among authors: pilon thomas sa. Nat Med. 2021 Aug;27(8):1410-1418. doi: 10.1038/s41591-021-01462-y. Epub 2021 Aug 12. Nat Med. 2021. PMID: 34385708 Free PMC article. Clinical Trial.
Fucosylation of HLA-DRB1 regulates CD4+ T cell-mediated anti-melanoma immunity and enhances immunotherapy efficacy.
Lester DK, Burton C, Gardner A, Innamarato P, Kodumudi K, Liu Q, Adhikari E, Ming Q, Williamson DB, Frederick DT, Sharova T, White MG, Markowitz J, Cao B, Nguyen J, Johnson J, Beatty M, Mockabee-Macias A, Mercurio M, Watson G, Chen PL, McCarthy S, MoranSegura C, Messina J, Thomas KL, Darville L, Izumi V, Koomen JM, Pilon-Thomas SA, Ruffell B, Luca VC, Haltiwanger RS, Wang X, Wargo JA, Boland GM, Lau EK. Lester DK, et al. Among authors: pilon thomas sa. Nat Cancer. 2023 Feb;4(2):222-239. doi: 10.1038/s43018-022-00506-7. Epub 2023 Jan 23. Nat Cancer. 2023. PMID: 36690875 Free PMC article.
The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling.
Mohamed E, Sierra RA, Trillo-Tinoco J, Cao Y, Innamarato P, Payne KK, de Mingo Pulido A, Mandula J, Zhang S, Thevenot P, Biswas S, Abdalla SK, Costich TL, Hänggi K, Anadon CM, Flores ER, Haura EB, Mehrotra S, Pilon-Thomas S, Ruffell B, Munn DH, Cubillos-Ruiz JR, Conejo-Garcia JR, Rodriguez PC. Mohamed E, et al. Among authors: pilon thomas s. Immunity. 2020 Apr 14;52(4):668-682.e7. doi: 10.1016/j.immuni.2020.03.004. Immunity. 2020. PMID: 32294407 Free PMC article.
Tumor-infiltrating lymphocytes: A new hope.
Sarnaik AA, Hwu P, Mulé JJ, Pilon-Thomas S. Sarnaik AA, et al. Among authors: pilon thomas s. Cancer Cell. 2024 Aug 12;42(8):1315-1318. doi: 10.1016/j.ccell.2024.06.015. Epub 2024 Jul 18. Cancer Cell. 2024. PMID: 39029463 Review.
Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patients.
Hall MS, Teer JK, Yu X, Branthoover H, Snedal S, Rodriguez-Valentin M, Nagle L, Scott E, Schachner B, Innamarato P, Hall AM, Blauvelt J, Rich CJ, Richards AD, Ceccarelli J, Langer TJ, Yoder SJ, Beatty MS, Cox CA, Messina JL, Abate-Daga D, Mule JJ, Mullinax JE, Sarnaik AA, Pilon-Thomas S. Hall MS, et al. Among authors: pilon thomas s. J Immunother Cancer. 2023 Oct;11(10):e007288. doi: 10.1136/jitc-2023-007288. J Immunother Cancer. 2023. PMID: 37802604 Free PMC article.
Modulating the polyamine/hypusine axis controls generation of CD8+ tissue-resident memory T cells.
Elmarsafawi AG, Hesterberg RS, Fernandez MR, Yang C, Darville LN, Liu M, Koomen JM, Phanstiel O 4th, Atkins R, Mullinax JE, Pilon-Thomas SA, Locke FL, Epling-Burnette PK, Cleveland JL. Elmarsafawi AG, et al. Among authors: pilon thomas sa. JCI Insight. 2023 Sep 22;8(18):e169308. doi: 10.1172/jci.insight.169308. JCI Insight. 2023. PMID: 37581943 Free PMC article.
Immunotherapy on acid: opportunities and challenges.
Damgaci S, Enriquez-Navas PM, Pilon-Thomas S, Guvenis A, Gillies RJ, Ibrahim-Hashim A. Damgaci S, et al. Among authors: pilon thomas s. Eur J Clin Nutr. 2020 Aug;74(Suppl 1):3-6. doi: 10.1038/s41430-020-0683-7. Eur J Clin Nutr. 2020. PMID: 32873950 Free PMC article. Review. No abstract available.
Epigenetic state determines the in vivo efficacy of STING agonist therapy.
Falahat R, Berglund A, Perez-Villarroel P, Putney RM, Hamaidi I, Kim S, Pilon-Thomas S, Barber GN, Mulé JJ. Falahat R, et al. Among authors: pilon thomas s. Nat Commun. 2023 Mar 22;14(1):1573. doi: 10.1038/s41467-023-37217-1. Nat Commun. 2023. PMID: 36949064 Free PMC article.
Current State of Cell Therapies for Genitourinary Malignancies.
Alkhouli MA, Bazargan S, Pilon-Thomas S, Poch M, Chahoud J. Alkhouli MA, et al. Among authors: pilon thomas s. Cancer J. 2022 Jul-Aug 01;28(4):294-300. doi: 10.1097/PPO.0000000000000604. Cancer J. 2022. PMID: 35880939 Review.
90 results